NEW YORK — Definium Therapeutics, Inc. (Nasdaq: DFTX) has announced the pricing of an underwritten public offering that is expected to generate approximately $700 million in gross proceeds. The late-stage clinical biopharmaceutical company, focused on developing therapeutics for psychiatric and neurological disorders, priced 20,588,236 common shares at $34.00 per share.
The offering, which was upsized from initial expectations, includes shares offered directly by Definium. These proceeds will be utilized before deducting underwriting discounts, commissions, and other associated expenses.
Furthermore, Definium has provided the underwriters with a 30-day option to purchase an additional 3,088,235 common shares at the same public offering price, less any underwriting discounts and commissions. This option allows for further capital infusion should market conditions and underwriter discretion permit.
The capital raised is anticipated to support the company’s ongoing development of its next-generation therapeutics aimed at addressing the root causes of complex psychiatric and neurological conditions. The successful pricing of this substantial offering underscores investor confidence in Definium’s pipeline and its potential to bring innovative treatments to market.
